Endothelial cell implantation and survival within experimental gliomas.
The delivery of therapeutic genes to primary brain neoplasms opens new opportunities for treating these frequently fatal tumors. Efficient gene delivery to tissues remains an important obstacle to therapy, and this problem has unique characteristics in brain tumors due to the blood-brain and blood-tumor barriers. The presence of endothelial mitogens and vessel proliferation within solid tumors suggests that genetically modified endothelial cells might efficiently transplant to brain tumors. Rat brain endothelial cells immortalized with the adenovirus E1A gene and further modified to express the beta-galactosidase reporter were examined for their ability to survive implantation to experimental rat gliomas. Rats received 9L, F98, or C6 glioma cells in combination with endothelial cells intracranially to caudate/putamen or subcutaneously to flank. Implanted endothelial cells were identified by beta-galactosidase histochemistry or by polymerase chain reaction in all tumors up to 35 days postimplantation, the latest time examined. Implanted endothelial cells appeared to cooperate in tumor vessel formation and expressed the brain-specific endothelial glucose transporter type 1 as identified by immunohistochemistry. The proliferation of implanted endothelial cells was supported by their increased number within tumors between postimplantation days 14 and 21 (P = 0.015) and by their expression of the proliferation antigen Ki67. These findings establish that genetically modified endothelial cells can be stably engrafted to growing gliomas and suggest that endothelial cell implantation may provide a means of delivering therapeutic genes to brain neoplasms and other solid tumors. In addition, endothelial implantation to brain may be useful for defining mechanisms of brain-specific endothelial differentiation.
Lal
B
B
Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205.
Indurti
R R
RR
Couraud
P O
PO
Goldstein
G W
GW
Laterra
J
J
D017500:Adenovirus E1A Proteins / Q000032:analysis / Q000096:biosynthesis; D000818:Animals; D001483:Base Sequence; D001932:Brain Neoplasms / Q000473:pathology*; D002421:Caudate Nucleus; D002460:Cell Line; D002470:Cell Survival; D017690:Cell Transplantation; D017931:DNA Primers; D004730:Endothelium, Vascular / Q000166:cytology*; D005814:Genes, Viral; D015316:Genetic Therapy / Q000379:methods; D005910:Glioma / Q000473:pathology*; D008969:Molecular Sequence Data; D016133:Polymerase Chain Reaction; D011699:Putamen; D051381:Rats; D011916:Rats, Inbred F344; D012091:Repetitive Sequences, Nucleic Acid; D001616:beta-Galactosidase / Q000032:analysis / Q000096:biosynthesis
D017500:Adenovirus E1A Proteins; D017931:DNA Primers; D001616:beta-Galactosidase